An 8-week Phase II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 24 or 32 Week Follow-up to Evaluate the Efficacy of rhNGF 20 µg/ml vs Vehicle in Patients With Stage 2 and 3 Neurotrophic Keratitis
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2019
Price : $35 *
At a glance
- Drugs Cenegermin (Primary)
- Indications Keratitis
- Focus Therapeutic Use
- Sponsors Dompe Spa
- 22 Aug 2018 According to a Dompe media release, the U.S. Food and Drug Administration (FDA) has approved Oxervate (cenegermin-bkbj ophthalmic solution) for the treatment of neurotrophic keratitis (NK).
- 22 Aug 2018 Topline data from this confirmatory study were presented at the 2017 Congress of the European Society of Ophthalmology, according to a Dompe media release.
- 30 Jul 2018 Status changed from recruiting to completed.